Floatz logo

Sargramostim

Testicular Germ Cell Tumor

Cancer Treatment Centers of Americaprotein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Testicular Germ Cell Tumor cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 2BBB
FILGRASTIM
University of Southampton
Phase 2BBB
Carboplatin
City of Hope Medical Center
Phase 2BBB
Ifosfamide
City of Hope Medical Center
Phase 2BBB
Cyclophosphamide
Barbara Ann Karmanos Cancer Institute
Phase 2BB

View all 48 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →